Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-X-C motif chemokine ligand 9 (CXCL9), CXCL10, and CXCL11 are a group of pro-inflammatory cytokines that serve as the primary ligands for the G protein-coupled receptor CXCR3 (UniProt P49682). These chemokines are strongly induced by interferon-gamma (IFN-gamma) and are produced by various cell types, including monocytes, endothelial cells, and fibroblasts (PMID: 21849401). Their primary biological role is to direct the chemotaxis of Th1-type CD4+ T cells, CD8+ T cells, and natural killer (NK) cells to sites of infection, injury, or malignancy (PMID: 25712153). In autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease, the overproduction of these chemokines drives chronic inflammation and tissue damage (PMID: 28273817). In the context of cancer, they often facilitate the recruitment of tumor-infiltrating lymphocytes, which can enhance the efficacy of immunotherapies, though they may also influence angiogenesis (PMID: 30619100). Therapeutic strategies targeting this axis include monoclonal antibodies like eldelumab, which specifically neutralizes CXCL10, and small-molecule antagonists that block the CXCR3 receptor (PMID: 26351881). Monitoring the levels of these chemokines in serum or tissue is often used as a biomarker for interferon activity and treatment response in various inflammatory diseases. Because they are critical for host defense, therapeutic inhibition of these ligands carries potential risks of increased susceptibility to certain viral or bacterial infections.
Neutralization of pro-inflammatory chemokine ligands to prevent their binding to the CXCR3 receptor, thereby inhibiting the recruitment of Th1-type immune cells to inflamed tissues.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10), and C-X-C motif chemokine ligand 11 (CXCL11) (CXCL9/CXCL10/CXCL11).